Patents by Inventor Michael Climo

Michael Climo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8198231
    Abstract: Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include ?-lactams and glycopeptides.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: June 12, 2012
    Assignee: Nutrition 21, Inc.
    Inventors: Michael Climo, Ellen Murphy, Gordon Archer
  • Publication number: 20060246055
    Abstract: Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include ?-lactams and glycopeptides.
    Type: Application
    Filed: June 2, 2006
    Publication date: November 2, 2006
    Applicant: Nutrition 21
    Inventors: Michael Climo, Ellen Murphy, Gordon Archer
  • Patent number: 7122514
    Abstract: Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include ?-lactams and glycopeptides.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: October 17, 2006
    Assignee: Nutrition 21, Inc.
    Inventors: Michael Climo, Ellen Murphy, Gordon Archer
  • Patent number: 7078377
    Abstract: Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include ?-lactams and glycopeptides.
    Type: Grant
    Filed: September 19, 2000
    Date of Patent: July 18, 2006
    Assignee: Nutrition 21, Inc.
    Inventors: Michael Climo, Ellen Murphy, Gordon Archer
  • Publication number: 20030199432
    Abstract: Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include &bgr;-lactams and glycopeptides.
    Type: Application
    Filed: April 16, 2003
    Publication date: October 23, 2003
    Inventors: Michael Climo, Ellen Murphy, Gordon Archer
  • Patent number: 6569830
    Abstract: Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include &bgr;-lactams and glycopeptides.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: May 27, 2003
    Assignee: Ambi, Inc.
    Inventors: Michael Climo, Ellen Murphy, Gordon Archer